Compare Humana Inc (HUM) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Moody's Corporation — how do they compare? Humana Inc trades at $437.41 (market cap $47.61B), while Moody's Corporation trades at $458.77 (market cap $77.87B). The key difference: Moody's Corporation is the larger of the two by market cap, and Moody's Corporation pays the higher dividend (0.92%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Moody's Corporation for 132 Days on average.
| HUM | MCO | |
|---|---|---|
Market Cap | $47.61B | $77.87B |
Volume | 1,827,332 | 633,412 |
Sector | Health | Financials |
52-Week High | $409.85 | $539.61 |
52-Week Low | $163.67 | $412.23 |
Typical Hold Time | 53 Days | 132 Days |
Enterprise Value | $54.97B | $83.89B |
Dividend Yield | 0.89% | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Moody's Corporation (MCO) trades at $458.69, up 1.41% with strong fundamentals including 34.25% net income margin and 80.15% ROE. The stock shows bearish technical signals but has consistently beaten earnings estimates in recent quarters. Recent developments include a minority stake acquisition in Philippine Rating Services and continued leadership in risk analytics, with the company ranking #1 in Chartis RiskTech100 for the fifth consecutive year.
Despite technical weakness, Moody's maintains strong profitability and analyst support with 56% buy ratings and a $536.40 consensus target. Key risks include high valuation multiples and potential market volatility, but the company's dominant market position and consistent earnings growth support long-term investment appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
